Cancer

Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa

Published in Blood Weekly, May 28th, 2009

Data from a study of managed-care cancer patients receiving chemotherapy and newly treated with erythropoiesis-stimulating agents (ESAs) found that the cumulative ESA cost with Epoetin alfa (EPO) was 29 percent lower than treatment with darbepoetin alfa (DARB). The analysis, published in the Spring issue of the Journal of Medical Economics, was sponsored by Centocor Ortho Biotech Services, LLC.

The retrospective cohort study of 10,928 patients investigated the current real-world dosing patterns and associated ESA costs in an adult cancer chemotherapy population. The data showed that the cumulative ESA cost was $4,321 for patients receiving EPO vs. $6,089 for DARB...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2009-05-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry